KFI
MDGL icon

Kachkovsky & Fisher Inc’s Madrigal Pharmaceuticals MDGL Stock Holding History

Kachkovsky & Fisher Inc’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Buy
+800
New +$410K 0.41% 44

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kachkovsky & Fisher Inc's MDGL Position: Q2 2026 in Review

Kachkovsky & Fisher Inc opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 800 shares worth $430K. The stake represents 0.41% of the portfolio and ranks #44 among its holdings.

414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Kachkovsky & Fisher Inc held 800 shares of Madrigal Pharmaceuticals worth $430K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Kachkovsky & Fisher Inc position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.41% of Kachkovsky & Fisher Inc's portfolio in Q2 2026, its #44 holding.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Kachkovsky & Fisher Inc's 13F filing for Q2 2026, filed 8 Sep 2026.